From Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
From Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
Am J Ophthalmol. 2022 Aug;240:79-98. doi: 10.1016/j.ajo.2022.02.011. Epub 2022 Feb 25.
To summarize the current evidence on COVID-19 vaccine-associated ocular adverse events.
Narrative literature review.
The literature search was conducted in August 2021 using 4 electronic databases: MEDLINE, EMBASE, PubMed, and the Cochrane Database of Systematic Reviews. Population-based pharmacovigilance surveillance data were retrieved from all governmental agencies participating in the World Health Organization (WHO) Programme for International Drug Monitoring with publicly available online adverse event databases in English.
A small number of case reports have documented uveitis flares and acute corneal graft rejection occurring within the first 3 weeks following immunization, while isolated cases of optic neuropathies, retinal conditions, scleritis, and herpetic eye disease have also been highlighted. However, data from population-based pharmacovigilance surveillance systems suggest that the prevalence of vaccination-associated ocular adverse events are very rare.
Vaccination-associated ocular adverse events are rare, and there is currently no substantive evidence to counterweigh the overwhelming benefits of COVID-19 immunization in patients with pre-existing ophthalmic conditions.
总结与 COVID-19 疫苗相关的眼部不良事件的现有证据。
叙述性文献综述。
文献检索于 2021 年 8 月进行,使用了 4 个电子数据库:MEDLINE、EMBASE、PubMed 和 Cochrane 系统评价数据库。从所有参与世界卫生组织(WHO)国际药物监测规划的政府机构中检索了基于人群的药物警戒监测数据,这些数据来自具有英语在线不良事件数据库的公共机构。
少数病例报告记录了在免疫接种后 3 周内出现的葡萄膜炎发作和急性角膜移植排斥反应,而孤立的视神经病变、视网膜疾病、巩膜炎和疱疹性眼病病例也被强调。然而,基于人群的药物警戒监测系统的数据表明,与疫苗接种相关的眼部不良事件的发生率非常罕见。
与疫苗接种相关的眼部不良事件很少见,目前没有实质性证据可以抵消 COVID-19 免疫接种对患有先前存在的眼部疾病的患者的巨大益处。